Philippines - English - FDA (Food And Drug Administration)

hospira philippines, inc. - cefoxitin (as sodium) - powder for injection - 1g

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefoxitin sodium 1 g - powder for injection - 1 g - active: cefoxitin sodium 1 g - cefoxitin actavis is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. cefoxitin actavis has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefoxitin sodium 2 g - powder for injection - 2 g - active: cefoxitin sodium 2 g - cefoxitin actavis is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. cefoxitin actavis has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

United States - English - NLM (National Library of Medicine)

apotex corporation - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin. cefoxitin for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by

United States - English - NLM (National Library of Medicine)

apotex corporation - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

United States - English - NLM (National Library of Medicine)

rebel distributors corp - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater than the potential clinical benefits of anticoagulation, such as: warfarin sodium tablets are contraindicated in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus in utero. furthermore, there have been reports of birth malformations in children born to mothers who

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefoxitin sodium 1.051 g equivalent to cefoxitin 1 g - powder for injection - 1 g - active: cefoxitin sodium 1.051 g equivalent to cefoxitin 1 g - hospira™ cefoxitin sodium powder for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology) peritonitis and other intraabdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. hospira™ cefoxitin sodium powder for injection has a high degree of stability against betalactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. hospira™ cefoxitin sodium powder for injection can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscous perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

Namibia - English - Namibia Medicines Regulatory Council

aspen pharmacare - cefoxitin as sodium - injection - cefoxitin sodium 1g

Namibia - English - Namibia Medicines Regulatory Council

aspen pharmacare - cefoxitin as sodium - injection - cefoxitin sodium 2g